PT-141

• The defensible B2B value is a form-defined analytical or research material for melanocortin-receptor assays, ligand-binding and signalling studies, identity and impurity method development, formulation compatibility and controlled preclinical models
• Pivotal trials support only the labelled finished drug and population, with modest absolute efficacy differences and substantial nausea
• Early male or intranasal studies do not create an approved indication or a claim for this SKU.

CAS

189691-06-3

Formula

C₅₀H₆₈N₁₄O₁₀ (free base)

Molecular weight

1025.2 g/mol

Appearance

White to off-white lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Follow lot-specific stability data for the declared free-base or acetate material. Protect from light and moisture and verify temperature-excursion, oxidation, deamidation, hydrolysis, adsorption and aggregate controls. The room-temperature instruction for Vyleesi's formulated prefilled autoinjector cannot establish storage or solution hold time for a lyophilized RUO vial.

MOQ

1 kit (10 vials) per SKU

Lead time

10–18 days

Bremelanotide is a synthetic N-acetylated cyclic heptapeptide melanocortin-receptor agonist related to alpha-MSH analogues. FDA approved Vyleesi, a defined bremelanotide-acetate injection, in 2019 for a limited acquired, generalized HSDD population. That approval applies to the sponsor's finished formulation and device; it does not approve generic PT-141 powder, male use, performance enhancement or other routes. The RUO page therefore uses the label as evidence context and identity support, not as administration guidance.

• Appropriate work includes receptor-binding and functional signalling assays, structure-activity research, cyclic-peptide identity and stereochemical methods, free-base/acetate equivalence, impurity and degradation profiling, formulation compatibility and controlled preclinical models
• HSDD treatment is an indication of Vyleesi only; male erectile dysfunction, postmenopausal use, sexual-performance enhancement, appetite effects and self-injection are not approved or validated uses of this SKU.

Bremelanotide is a melanocortin-receptor agonist with activity at multiple receptor subtypes. The current FDA label states that the mechanism by which it improves HSDD is unknown. MC4R-centred hypotheses and neuroimaging findings can guide research, but they do not establish single-receptor selectivity, eliminate MC1R-related pigmentation risk or prove a complete central signalling pathway.

• This RUO material has no human safety qualification
• The approved Vyleesi label includes transient blood-pressure increases and heart-rate reduction, contraindications for uncontrolled hypertension or known cardiovascular disease, focal hyperpigmentation that may not resolve, nausea, flushing, injection-site reactions, headache and vomiting, plus reproductive-use limitations
• Those risks contradict claims that PT-141 has no cardiovascular or pigmentation effects
• Chemical purity cannot establish sterile-drug safety, and this vial must not be used as a substitute for the prescription product.

Interactions reported in the literature

• In finished-product labelling, bremelanotide may slow gastric emptying and alter absorption of oral medicines, and can significantly reduce systemic exposure to orally administered naltrexone
• These are clinical label facts, not combination instructions for RUO powder
• For laboratory work, evaluate buffer, pH, counterion, surfaces, proteases, oxidants and receptor-assay controls; no validated compatibility matrix exists for mixing this material with PDE5 inhibitors, melanocortin analogues, hormones or other peptides.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• The COA must state free base versus acetate, acetate stoichiometry and assay on a free-base or as-is basis
• Require high-resolution intact mass, MS/MS or mapping, sequence and ring-closure confirmation, D-Phe stereochemical control, N-terminal acetylation, C-terminal free acid, chromatographic purity and identified impurity profile, peptide content, acetate, water, residual solvents, elemental impurities, counterion and mass balance, plus lot stability
• If a buyer needs bioburden or endotoxin limits for a non-administration assay, they must be specified separately; neither test establishes sterility or human-use suitability.

Follow lot-specific stability data for the declared free-base or acetate material. Protect from light and moisture and verify temperature-excursion, oxidation, deamidation, hydrolysis, adsorption and aggregate controls. The room-temperature instruction for Vyleesi's formulated prefilled autoinjector cannot establish storage or solution hold time for a lyophilized RUO vial.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• Current DailyMed labelling distinguishes bremelanotide acetate in the Vyleesi finished product from free-base molecular mass and states that the clinical mechanism is unknown. PubChem CID 9941379 supports free-base identity, formula and CAS 189691-06-3. The FDA approval package and multidisciplinary review define the limited approved indication and benefit-risk basis. Kingsberg 2019 reports the pivotal trials; Simon 2019 is an open-label extension with substantial attrition; subgroup and neuroimaging analyses remain secondary or mechanistic. No source converts Vyleesi approval into approval of this RUO powder.

1. 01

   Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

   Obstetrics & Gynecology · 2019 · peer-reviewed original research (pivotal RECONNECT phase 3 RCTs)

   Open source
2. 02

   Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

   Obstetrics & Gynecology · 2019 · peer-reviewed original research (52-week open-label extension study)

   Open source
3. 03

   Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide

   Journal of Women's Health (Larchmont) · 2022 · peer-reviewed original research (integrated post-hoc subgroup analysis of pivotal trials)

   Open source
4. 04

   Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

   The Journal of Clinical Investigation · 2022 · peer-reviewed original research (randomized, double-blind, placebo-controlled crossover neuroimaging study)

   Open source
5. 05

   VYLEESI (bremelanotide injection) Prescribing Information

   DailyMed · 2025 · current U.S. prescription-drug label

   Open source
6. 06

   Vyleesi NDA 210557 Approval Package

   FDA Drugs@FDA · 2019 · U.S. government approval record

   Open source
7. 07

   Vyleesi Multi-Discipline Review and Evaluation

   FDA Center for Drug Evaluation and Research · 2019 · U.S. government scientific benefit-risk review

   Open source
8. 08

   PubChem Compound Summary: Bremelanotide

   PubChem · 2026 · authoritative chemical identity database

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order